gdc

Drugs for Myelodysplastic Syndromes

Here are the financial support services available to patients receiving treatment for Myelodysplastic Syndromes.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with myelodysplastic or myeloproliferative disease associated with PDGFR gene rearrangements.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Gleevec $10 Co-Pay Card

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Gleevec for free for 1 year, or until prescription drug coverage becomes available to them.

Revlimid (lenalidomide)

Drug company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of patients with low- or intermediate-risk myelodysplastic syndromes.

Celgene Patient Support offers 3 financial assistance programs for patients using Revlimid:

Celgene Commercial Co-pay Program

This program reduces copay for Revlimid to $25 or less for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Vidaza (azacitidine)

Drug company: Celgene
800-931-8691

Vidaza is a nucleoside metabolic inhibitor used for the treatment of patients with myelodysplastic syndromes.

Celgene Patient Support offers 1 financial assistance program for patients using Vidaza:

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover medication, who meet certain financial criteria may qualify for the program.

Table. Drugs Prescribed for Myelodysplastic Syndromes

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Vidaza (azacitidine)
  • Drug company
  • Celgene
  • Indication
  • Myelodysplastic syndromes
  • Patient support services
  • Celgene Patient Assistance Program
    800-931-8691
Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country